Last reviewed · How we verify
A-prexa
A-prexa is an antipsychotic medication that works by blocking dopamine receptors in the brain.
A-prexa is an antipsychotic medication that works by blocking dopamine receptors in the brain. Used for Treatment of schizophrenia, Treatment of bipolar disorder.
At a glance
| Generic name | A-prexa |
|---|---|
| Sponsor | HK inno.N Corporation |
| Drug class | Atypical antipsychotic |
| Target | D2 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
A-prexa is a partial antagonist of the D2 receptor, which helps to reduce the symptoms of psychosis. It also has some affinity for the serotonin 5-HT2A receptor, which may contribute to its therapeutic effects.
Approved indications
- Treatment of schizophrenia
- Treatment of bipolar disorder
Common side effects
- Weight gain
- Dizziness
- Headache
- Nausea
- Somnolence
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- A-prexa CI brief — competitive landscape report
- A-prexa updates RSS · CI watch RSS
- HK inno.N Corporation portfolio CI